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OBJECTIVES Using data from the Multicenter UnSustained Tachycardia Trial (MUSTT), we examined
the factors used to select antiarrhythmic drug therapy and their impact on outcomes.
BACKGROUND The MUSTT examined the use of programmed ventricular stimulation (PVS) to guide
antiarrhythmic therapy in patients with coronary arteriosclerosis, left ventricular dysfunction
and asymptomatic, unsustained ventricular tachycardia (VT). Trial outcomes may reflect
factors used to select antiarrhythmic drug therapy.
METHODS We compared subgroups of patients with inducible sustained VT randomized to PVS-guided
antiarrhythmic therapy (n 5 351), in particular those receiving PVS-guided antiarrhythmic
drug therapy (n 5 142) versus no antiarrhythmic therapy (controls, n 5 353).
RESULTS “Effective” antiarrhythmic drug therapy (i.e., the term “effective” was used to denote therapy
that resulted in noninducible VT or hemodynamically stable induced VT) was found for 142
of the 351 patients (43%), most often at the first or second PVS session (125/142, 88%).
Mortality among the 142 patients did not differ from that among control patients. Of these
142 patients, the PVS end point was noninducibility in 91 patients and stable VT in 51
patients. Mortality did not differ between these two groups either, but arrhythmia was
numerically more frequent in the PVS-induced stable VT group. Mortality was greatest in the
few patients receiving propafenone (unadjusted p 5 0.07, adjusted p 5 0.14 vs. controls), but
mortality with all agents did not differ from that of controls, even after adjustment.
CONCLUSIONS Even when presenting the results as favorably as possible, we found no benefit with
PVS-guided drug therapy in patients with clinical unsustained VT who had inducible
sustained VT. These findings are unaltered by using different end points for PVS or
considering the response to individual drugs. (J Am Coll Cardiol 2001;38:344–51) © 2001
by the American College of Cardiology
The Multicenter UnSustained Tachycardia Trial (MUSTT)
was a randomized, controlled trial of programmed ventric-
See page 352
ular stimulation (PVS) for management of patients with
coronary arteriosclerosis, left ventricular dysfunction and
asymptomatic, unsustained ventricular tachycardia (VT) (1).
The main trial was analyzed on an intention-to-treat basis.
In the main trial and the registry, arrhythmic death or
nonfatal cardiac arrest was reported as the primary end point
and all-cause mortality as a key secondary end point (2,3).
In MUSTT, antiarrhythmic drug therapy that prevented
VT induction or made induced VT hemodynamically stable
conferred no survival benefit over no antiarrhythmic therapy
(2). This finding was unexpected (4). The main results of
MUSTT may partly reflect the choice of agents and
methods for PVS. We examined these factors with regard to
the end points of death and ventricular arrhythmias.
METHODS
The MUSTT protocol has been reported (1). In brief, we
identified patients with coronary arteriosclerosis, an ejection
fraction #0.40 and asymptomatic, nonsustained VT on
electrocardiography. Major exclusions included previous
From the *University of Calgary, Calgary, Alberta, Canada; †Montreal Heart Institute,
Montreal, Quebec, Canada; ‡Duke Clinical Research Institute, Durham, North Carolina;
§Temple University Hospital School of Medicine, Philadelphia, Pennsylvania; \Sacre
Coeur Hospital, Montreal, Quebec, Canada; ¶Mayo Clinic Foundation, Rochester,
Minnesota; #Veteran’s Administration Medical Center, Ann Arbor, Michigan; **Rhode
Island Hospital, Providence, Rhode Island; ††Rush-Presbyterian Hospital, Chicago,
Illinois; ‡‡Thoracic and Cardiovascular Institute, Lansing, Michigan; §§Columbia
University Medical Center, New York, New York; and \ \Veteran’s Administration
Medical Center, Washington, District of Columbia. Supported by C.R. Bard, Inc.; Berlex
Laboratories, Inc.; Boehringer-Ingelheim Pharmaceuticals, Inc.; Merck & Co, Inc.;
Guidant Corporation; Knoll Pharmaceutical Co.; Medtronic, Inc.; Searle Pharmaceutical;
Ventritex; Wyeth-Ayerst Laboratories and grants U01HL45700 and U01HL45726 from
the National Heart, Lung, and Blood Institute.
Manuscript received November 10, 2000; revised manuscript received March 22,
2001, accepted April 26, 2001.
Journal of the American College of Cardiology Vol. 38, No. 2, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01402-4
syncope, sustained VT or ventricular fibrillation .48 h after
acute myocardial infarction onset; nonsustained VT occur-
ring only with reversible causes; and symptomatic, unsus-
tained VT requiring treatment.
PVS protocol. Programmed ventricular stimulation was
performed as described (1), after antiarrhythmic drugs were
stopped, and included #3 extrastimuli at two right ventric-
ular sites after two ventricular pacing-cycle lengths. Patients
with inducible, sustained monomorphic VT induced by up
to three extrastimuli, or sustained polymorphic VT induced
by one or two extrastimuli, were randomized equally to
PVS-guided antiarrhythmic therapy or no antiarrhythmic
therapy. To declare a drug therapy potentially “effective,”
the entire stimulation protocol had to be completed (three
extrastimuli, two cycle lengths, two sites).
Serial antiarrhythmic drug trials. Patients randomized to
PVS-guided therapy underwent serial drug testing. In trial
1, there was three-way randomization between class 1A
agents (quinidine, disopyramide or procainamide, chosen by
investigators), propafenone or sotalol. If treatment failed to
control VT induction in trial 1, investigators could choose
to implant an implantable cardioverter defibrillator (ICD)
or attempt another drug trial. In trial 2, patients were
randomized to one of the therapies not used in trial 1 or to
a combination of mexiletine and a class 1A agent. If this
treatment failed, investigators could implant an ICD or
attempt additional trials, which could include treatment
with amiodarone or randomization to any trial 1 or 2 drug
that had not previously failed. All patients whose PVS-
induced VT was not controlled by antiarrhythmic drug
therapy or who developed intolerable adverse drug effects
were offered ICD implantation.
Programmed ventricular stimulation was repeated four to
five half-lives after antiarrhythmic drug therapy was given
(after $1 week for amiodarone). If sustained VT was
induced during a trial, the patient was observed for 5 min
during VT (if clinically appropriate) to assess hemodynamic
stability. If the patient had no angina, syncope or severe
presyncope and the systolic blood pressure was
.80 mm Hg, the VT was considered to be hemodynami-
cally stable. If ,15 consecutive complexes of VT were
induced by PVS, VT was considered noninducible, and
long-term treatment with that antiarrhythmic drug therapy
was permitted. If no regimen could be found that rendered
VT noninducible, investigators could discharge patients
with antiarrhythmic drug therapy that resulted in hemody-
namically stable VT as defined above. Thus, “effective”
antiarrhythmic drug therapy was that which resulted in
noninducible VT or hemodynamically stable induced VT.
Follow-up. Patients were to be seen as outpatients one
month after discharge and every three months thereafter. If
a patient could not be seen at a center, follow-up was
conducted by telephone.
Study end points. The primary end point of the present
analysis was all-cause mortality. The secondary end point
was a “clinically important arrhythmia event,” defined as
arrhythmic death, resuscitated cardiac arrest or spontaneous,
sustained VT on electrocardiography. “Cardiac arrest” was
defined as sudden unconsciousness in a patient who had
been stable, requiring direct-current countershock to restore
blood pressure and rhythm.
Statistical analysis. This report is an as-treated analysis of
antiarrhythmic drug therapy. Patients were included in the
follow-up phase when effective antiarrhythmic drug therapy
was found after randomization; they were removed from
follow-up if an ICD was later implanted. Follow-up was
limited to two years from randomization. Any member of
the comparison group of patients randomized to no antiar-
rhythmic therapy was also removed from follow-up if an
ICD was implanted.
Continuous variables are summarized by using medians
(with 25th, 75th percentiles); discrete variables are repre-
sented as frequencies and percentages. All tests of signifi-
cance were two-tailed. Cumulative event rates were charac-
terized with Kaplan-Meier curves, with time from
randomization to the first event as the outcome variable (5).
The log-rank test was used to assess the significance of
differences between treatment subgroups (5). We adjusted
the log-rank p values for differences in known predictors of
mortality between subgroups (age, ejection fraction and
beta-adrenergic blocking agent use) (6) with the Cox
proportional hazards model (7).
RESULTS
In all, 704 patients with randomizable induced VT con-
sented to randomization: 353 were randomized to receive
no antiarrhythmic therapy, and 351 were randomized to
receive PVS-guided antiarrhythmic therapy. Of the latter
351 patients, 330 underwent $1 drug trial. Of the remain-
ing 21 patients, 11 had adverse effects during drug loading;
7 withdrew consent for PVS before receiving antiarrhythmic
drug therapy; 1 patient died during drug loading; 1 had a
nonfatal cardiac arrest; and 1 underwent bypass surgery,
after which VT was no longer inducible. This patient was
discharged without antiarrhythmic therapy.
Of the 142 patients (43%) for whom effective antiar-
rhythmic drug therapy was identified (91 noninducible, 51
stable VT), 88% had such therapy determined by one or two
PVS trials (Table 1). The maximum number of trials in any
patient was four (only six such patients). The proportion
whose effective antiarrhythmic therapy was due to nonin-
ducibility was low (19% of first trials) and fell after trial 1,
Abbreviations and Acronyms
ICD 5 implantable cardioverter defibrillator
MUSTT 5 Multicenter UnSustained Tachycardia Trial
PVS 5 programmed ventricular stimulation
VT 5 ventricular tachycardia
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whereas the proportion whose effective antiarrhythmic ther-
apy was assigned by hemodynamically stable VT increased
in later trials. Outcomes of stable VT were not recorded if
patients became noninducible at a later trial; therefore,
patients who actually had stable induced VT may be
underreported for earlier trials.
Of the 330 patients randomized to PVS-guided therapy
and having PVS at least once while taking an antiarrhyth-
mic drug, 88% had monomorphic VT induced at baseline;
the remainder had polymorphic VT induced. Effective
antiarrhythmic drug therapy was found for 41% of those
with monomorphic VT at baseline and for 55% of those
with polymorphic VT at baseline (p 5 0.10).
Of the agents assigned by randomization in trial 1,
propafenone was least likely to produce effective therapy
(10% in trial 1, 11% overall), compared with class 1A agents
(31% in trial 1, 29% overall) or sotalol (33% in trial 1, 35%
overall) (Table 2). However, these three groups of agents
were equally likely to produce stable VT (6%, 8% and 6%,
respectively). Amiodarone seemed to be quite efficacious in
the few cases when it was used in trial 1, but this largely
reflected the production of stable VT (15 of 51 trials or 29%
overall). Drug combinations rarely rendered the VT nonin-
ducible (five of 44 trials, 11%) but were equally likely to
produce stable VT (seven of 44 trials, 16%).
Survival did not differ between the 142 patients dis-
charged with effective antiarrhythmic drug therapy and
those randomized to no antiarrhythmic therapy (Fig. 1A).
Of patients discharged with effective antiarrhythmic drug
therapy, 50% of deaths were attributable to arrhythmic
causes, compared with 53% in patients discharged without
antiarrhythmic therapy. Survival did not differ even when
noninducible patients and those with stable induced VT
were analyzed separately (Fig. 1B). Among patients dis-
charged with noninducible VT, 52% of deaths were attrib-
uted to arrhythmic causes, compared with 46% in patients
with stable VT. Mortality in those patients receiving effec-
tive therapy, likewise, did not differ by monomorphic or
polymorphic VT induced at baseline (p 5 0.76, data not
shown). Clinically important ventricular arrhythmias oc-
curred more often in patients receiving effective antiarrhyth-
mic drug therapy (Fig. 2A), particularly in those with stable
inducible VT (Fig. 2B). The proportion of arrhythmic
events that resulted in arrhythmic death was 63% in patients
discharged without antiarrhythmic therapy, compared with
51% in patients discharged with effective antiarrhythmic
drug therapy. In patients discharged with noninducible VT,
the proportion of arrhythmic events that resulted in arrhyth-
mic death was 57%, compared with 43% in patients dis-
charged with stable inducible VT. The differences in overall
survival between groups were not statistically significant.
There was no difference in clinically important ventricular
arrhythmias by monomorphic or polymorphic VT induced
Table 1. Assignment of “Effective” Antiarrhythmic Drug
Therapy by Programmed Ventricular Stimulation, by Number of
Drug Trials
Drug
Trials (n)
Patients
Tested (n)
“Effective” Therapy, n (%)*
Noninducible Stable V Tach Total
1 330 64 (19) 21 (6) 85 (26)
2 148 20 (14) 20 (14) 40 (27)
$3 51 7 (14) 10 (20) 17 (33)
*Noninducible denotes ,15 beats of V Tach; Stable V Tach indicates 5 min duration,
minor symptoms and systolic blood pressure .80 mm Hg.
V Tach 5 ventricular tachycardia.
Table 2. Assignment of “Effective” Antiarrhythmic Drug Therapy by Programmed Ventricular
Stimulation, by Drug Class and PVS End Point
Trial 1 Trial 2 Trial >3 Total
Class 1A drugs, n (%)* (n 5 172) (n 5 52) (n 5 2) (n 5 226)
Noninducible 42 (24) 6 (12) 1 (50) 49 (22)
Stable ventricular tachycardia 11 (6) 6 (12) 0 17 (8)
Total 53 (31) 12 (23) 1 (50) 66 (29)
Propafenone, n (%) (n 5 97) (n 5 23) (n 5 3) (n 5 123)
Noninducible 4 (4) 1 (4) 1 (33) 6 (5)
Stable ventricular tachycardia 6 (6) 1 (4) 0 7 (6)
Total 10 (10) 2 (9) 1 (33) 13 (11)
Sotalol, n (%) (n 5 57) (n 5 22) (n 5 6) (n 5 85)
Noninducible 17 (30) 6 (27) 2 (33) 25 (29)
Stable ventricular tachycardia 2 (4) 1 (5) 2 (33) 5 (6)
Total 19 (33) 7 (32) 4 (67) 30 (35)
Amiodarone, n (%) (n 5 3) (n 5 17) (n 5 31) (n 5 51)
Noninducible 1 (33) 2 (12) 3 (10) 6 (12)
Stable ventricular tachycardia 2 (67) 7 (41) 6 (19) 15 (29)
Total 3 (100) 9 (53) 9 (29) 21 (41)
Other agents, n (%)† (n 5 1) (n 5 34) (n 5 9) (n 5 44)
Noninducible 0 5 (15) 0 5 (11)
Stable ventricular tachycardia 0 5 (15) 2 (22) 7 (16)
Total 0 10 (29) 2 (22) 12 (27)
*Quinidine (n 5 159), procainamide (n 5 63) and disopyramide (n 5 4); †quinidine with mexiletine (n 5 37), disopyramide
with mexiletine (n 5 4), procainamide with mexiletine (n 5 2) and procainamide with acebutolol (n 5 1).
PVS 5 programmed ventricular stimulation.
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at baseline (p 5 0.75, data not shown). We also found no
significant difference in either outcome when we defined
noninducibility as ,5 beats (n 5 53) or 5 to 14 beats (n 5
38) of induced VT (data not shown).
Mortality did not differ whether effective antiarrhythmic
drug therapy was found in trial 1 versus trial 2 or later trials
(Fig. 3). With respect to clinically important ventricular
arrhythmias, outcomes tended to be better when therapy
was determined at trial 2 or later trials (not shown), but
these differences were not statistically significant.
Figure 4 shows overall survival for patients randomized to
no antiarrhythmic therapy and patients receiving effective
antiarrhythmic therapy by class of drug used. Twelve pa-
tients had effective antiarrhythmic therapy identified with
combinations of antiarrhythmic drugs (“Other” in Table 2).
Because these patients were receiving a class 1A agent with
mexiletine, we included their data with those of patients
given class 1A agents in Figure 4 (Table 3). Numerically,
survival was best with sotalol and worst with propafenone.
The results using clinically important arrhythmic events
(not shown) as an end point are similar to those for
mortality depicted in Figure 4.
There were some important differences in baseline char-
acteristics for the subgroups depicted in Figure 4 (Table 3).
Patients randomized to no antiarrhythmic drug therapy
were slightly younger than those receiving effective therapy,
Figure 1. Survival with effective antiarrhythmic drug therapy ([ADT]
heavy line) versus no antiarrhythmic therapy ([AT] light line), overall (A)
and among patients with noninducible versus stable, inducible ventricular
tachycardia (VT) (B).
Figure 2. Arrhythmia-free survival with effective antiarrhythmic drug
therapy ([ADT] heavy line) versus no antiarrhythmic therapy ([AT] light
line), overall (A) and among patients with noninducible versus stable
inducible ventricular tachycardia (VT) (B).
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significantly so for amiodarone. Ejection fractions were
higher in those treated with sotalol. Beta-blocker use was
highest in those randomized to no antiarrhythmic drug
therapy. All subgroups receiving antiarrhythmic drug ther-
apy had significantly fewer patients who were being treated
with beta-blocker therapy, most notably the subgroup given
Figure 3. Survival in patients receiving effective antiarrhythmic drug therapy found at drug trial 1 (solid line) versus trial 2 or later drug trials (broken line).
Figure 4. Survival with effective antiarrhythmic drug therapy (heavy line) versus no antiarrhythmic therapy ([AT] light line) by agent used: class 1A and
other antiarrhythmic agents (A), sotalol (B), propafenone (C) and amiodarone (D).
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amiodarone. Patients taking sotalol less often received
digitalis or nitrates.
DISCUSSION
The primary analysis of MUSTT suggested that PVS-
selected antiarrhythmic drug therapy confers no benefit (1).
We have extended this observation to include clinically
important ventricular arrhythmias, with evaluation of the
effects of various antiarrhythmic drugs and definitions of
“effective” antiarrhythmic drug therapy. Importantly, we
found that regardless of the agent(s) or definitions used, a
PVS-guided approach does not appear to select antiarrhyth-
mic drug therapy that provides a tangible benefit to this
group of patients.
The proportion of patients tested for whom effective
antiarrhythmic drug therapy was determined in MUSTT is
similar to that seen in studies of sustained ventricular
tachyarrhythmias (8,9). These studies often included more
drug trials, the end point of which was noninducibility. Few
patients in MUSTT had .2 PVS-guided antiarrhythmic
drug trials. The proportion tested whose VT became non-
inducible declined after trial 1, as has been reported in
patients with sustained ventricular tachyarrhythmias (10).
The MUSTT investigation is the first large trial to evaluate
hemodynamically stable VT as a prospective PVS end point.
About 30% of the patients for whom effective therapy was
determined had such therapy identified by this end point.
With respect to total mortality, hemodynamically stable VT
did not differ from noninducibility as an end point of PVS.
Observational studies have shown similar findings, most
notably with amiodarone (11). As noted in the study of
Waller et al. (11), however, clinically important ventricular
arrhythmia was more likely when hemodynamically stable
VT was used as the PVS end point. The overall results of
MUSTT might have quantitatively differed if noninducibil-
ity alone had been used as the PVS end point. Because most
patients had only one or two drug trials, however, more
patients in the PVS-guided arm would have been likely to
receive an ICD.
The most appropriate definition of “noninducibility”
remains controversial. The definition used by MUSTT
investigators (1) and others (8) was #14 beats of VT,
whereas some have used #4 beats (9). However, a random-
ized trial of these two measures strongly suggests that
long-term outcomes are better when #4 beats is used as the
PVS end point (12). We found no significant difference
between #4 and 5 to 14 beats of noninducible VT. A more
stringent definition of “noninducibility” in MUSTT might
have yielded a different overall result but would have been
likely to result in implantation of more ICDs. Whether the
number of trials played a role in the overall results is difficult
to explore, because most patients had only one or two trials.
The analysis chosen (first trial vs. second or further trials)
showed no difference. An observational study of this point
(10) suggests that the predictive value of the first few trials
is about the same; but after the third trial, long-term
arrhythmias are more frequent despite documented nonin-
ducibility. This observational study is difficult to compare
with ours, because of differences in the number of drug
trials, in the agents used, and in the end points of PVS.
The final factor regarding drug selection in MUSTT was
the agent used. Class 1A agents were used most often, alone
or with mexiletine, followed by sotalol and amiodarone.
Very few patients achieved effective therapy with
propafenone. The strongest trend was that mortality and
clinically important ventricular arrhythmias were more likely
in the few patients who achieved effective therapy with
propafenone. This potentially harmful effect of propafenone
Table 3. Baseline Characteristics by Discharge Medications
No
Therapy
Class IA
1 Other Sotalol Propafenone Amiodarone
(n 5 353) (n 5 78)* (n 5 30) (n 5 13) (n 5 21)
Age (yr) 66 (58, 72) 68 (60, 73) 69 (63, 72) 67 (62, 71) 70 (67, 73)†
Ejection fraction (%) 29 (22, 35) 25 (20, 34) 35 (26, 37)† 27 (23, 35) 30 (24, 35)
Male gender (%) 90 94 97 85 100
Caucasian (%) 86 85 93 100 76
Prior infarction (%) 93 97 90 92 95
Thrombolytics (%) 21 12 23 8 20
Angina (%) 71 73 63 85 62
Prior bypass (%) 56 54 67 62 43
Discharge medications (%)
Beta-blockers 51 27† — 23† 10†
Angiotensin-converting
enzyme inhibitors
77 73 70 69 62
Calcium blockers 25 22 20 46 33
Digitalis 53 53 33† 46 38
Diuretics 58 58 50 54 76
Nitrates 44 41 20† 54 33
Aspirin 63 62 73 69 52
*Quinidine (n 5 50), quinidine with mexiletine (n 5 11), procainamide (n 5 14), disopyramide with mexiletine (n 5 1) and
disopyramide (n 5 2); †p # 0.05 versus no therapy.
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is comparable to that seen in the Cardiac Arrest Study
Hamburg (CASH) (13). Patients taking the other agents
fared no differently from those randomized to no antiar-
rhythmic therapy.
Although the use of beta-blockers in MUSTT was at
least as common as in contemporary antiarrhythmic trials
(14,15), their level of use remained disappointing. Despite
the extensive literature showing a salutary benefit of these
drugs in patients with coronary disease (16), only slightly
over 50% of patients randomized to no antiarrhythmic
therapy received beta-blockers. Even fewer patients receiv-
ing PVS-guided antiarrhythmic drug therapy received these
agents. Certainly, this is understandable in the case of
sotalol, a fairly potent beta-blocker itself. Many physicians
avoid beta-blockers in patients taking amiodarone; but the
beta-blocking properties of amiodarone are quite weak, and
recent evidence (17) suggests that a beta-blocker and ami-
odarone combination may be particularly efficacious for
antiarrhythmic therapy.
A potential bias exists in that the subgroups in the present
analyses were not formed by randomization. Indeed, pa-
tients treated with sotalol had better ventricular systolic
function, which may explain their lesser use of digitalis and
nitrates. Thus, other than noting that propafenone seldom
produced PVS-guided effective therapy and may be harm-
ful, little can be said about individual drugs.
Clinical implications. When PVS-guided effective antiar-
rhythmic drug therapy was found and used, survival was no
better than it was without antiarrhythmic therapy. The
MUSTT data cannot be generalized to other groups, but,
with these findings, the overall utility of PVS-guided
antiarrhythmic drug therapy must be questioned. Implant-
able cardioverter defibrillator therapy has substantial benefit
in drug-resistant patients and should be considered early.
We cannot comment on the individual drug therapies most
likely to be beneficial based on these data, and antiarrhyth-
mic drug therapy currently is a secondary alternative for
most patients. Propafenone rarely produces effective therapy
in this population.
Study limitations. These results clearly illustrate the sub-
stantial loss of power and increased uncertainty that occurs
in subgroup analyses (18). Uncertainty is particularly evident
regarding the implication that propafenone may be harmful;
only 13 patients received this drug. That the subgroups were
not randomized introduces further uncertainty in interpret-
ing these results. Investigators were instructed to seek
noninducibility as the preferable end point for PVS but
could accept stable VT when noninducibility was not
achievable. The degree to which investigators adhered to
this directive probably varied and may have influenced the
results. Also, patients were excluded from analysis if they
received an ICD, and the majority were removed from
follow-up data after experiencing a cardiac arrest or sus-
tained VT. Some ICDs were implanted for syncope without
a documented tachyarrhythmia (11/39 [28%] vs. 1/26 [4%],
no therapy vs. PVS-guided therapy). The remainder re-
ceived ICDs for various reasons (7/39 [18%] vs. 16/26
[62%], no therapy vs. PVS-guided therapy). The high
proportion of ICD use in PVS-guided therapy in the latter
instance is entirely accounted for by the adverse effects of
antiarrhythmic drugs. The pattern of usage of ICDs con-
tributes to the present findings.
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